DNA fingerprinting with three different probes (33.15, 33.6, and a-globin 3'HVR) was investigated as a method for the determination of clonality in gastrointestinal tumors. In 29/44 carcinomas the tumor DNA showed clonal somatic mutations that were not seen in the corresponding peripheral blood and normal mucosa samples. The changes consisted of either novel fingerprint bands, losses of bands, or both. The probe 33.15 yielded the highest rate of abnormal DNA fingerprints (21/44 carcinomas). Sequential use of the probes increased the number of cases where clonal fingerprint markers could be detected. One out of five colorectal adenomas also showed a clonal loss of a fingerprint band. In two cases of gastric cancer, DNA from the metastatic tumor had a different DNA fingerprint from that found in the primary carcinoma. DNA fingerprinting offers a novel approach to determining clonality in tumors and may prove useful for the study of tumor progression.
Introduction
The determination of clonality of human tumors has important implications for the mechanisms of carcinogenesis. The discovery that a tumor has a monoclonal composition is consistent with a mutational theory of carcinogenesis: a mutation occurring within a single cell results in a tumor composed entirely of the progeny of that cell (1, 2) . Most human tumors investigated to date have been shown to be monoclonal (3) (4) (5) (6) . However, hereditary tumors such as hereditary neurofibromas may be of multiclonal origin since all the cells from which they originate have the potential to develop into tumors (7, 8) . Other mechanisms, for example aberrant differentiation processes, may also result in neoplasms with a polyclonal composition (9) . The practical value ofclonality determination is well illustrated by the lymphoproliferative disorders where the distinction can be made between a reactive process (polyclonal) and a neoplastic process (monoclonal) (10, 11) .
The assessment of clonality in tumor cell populations has traditionally depended on one of three approaches: the expression of a single allele of glucose-6-phosphate dehydrogenase within the tumor of a female patient heterozygous for an enzyme polymorphism (12) ; the determination that only a single Ig light chain (either lambda or kappa) is expressed on the surface of neoplastic B cells in lymphoproliferative disorders (13) ; and the demonstration of a specific cytogenetic abnormality (14) . More recently, the techniques of molecular genetics have enlarged the scope of these methods. For example, X-linked restriction fragment length polymorphisms can be used to study the clonality of tumors in a higher percentage of female patients than is feasible using the glucose-6-phosphate dehydrogenase isoenzymes (6) . The use of DNA probes for Ig and T cell receptor genes has permitted clonality to be assessed in a wide variety of lymphoid neoplasms including T cell tumors not expressing Ig light chains. Nevertheless, Xlinked restriction fragment length polymorphisms are limited to tumors of female patients, while Ig and T cell receptor gene probes are limited to lymphopoietic tumors.
DNA fingerprinting enables the detection of many unlinked autosomal hypervariable region (HVR)' loci simultaneously (15) (16) (17) . These loci have a particularly high mutation rate, possibly because they are hotspots for meiotic or mitotic recombination or sister chromatid exchange (15) . The combination ofthese two properties makes DNA fingerprint analysis an attractive approach for the detection of clonal somatic mutations in tumors. In a preliminary study of DNA fingerprints in a variety ofhuman cancers, 10 by the random-hexamer-primer method (23) . For hybridization with the Ml 3 recombinant probes filters were prehybridized in 50% formamide, 3X standard saline citrate (SSC) (150 mM sodium chloride, 15 mM sodium citrate, pH 7.0), 0.2% SDS, and 50 ,ug/ml heparin and hybridized at 37°C in the same buffer with the addition of 5% dextran sulfate and 200 sg/ml heparin. They were washed in I X SSC and 0.1% SDS at 61 'C. For DNA fingerprinting with the a-globin 3' HVR probe filters were prehybridized and hybridized at 61°C in 1.5X SSPE (270 mM sodium chloride, 15 mM sodium phosphate, pH 7.7, and 150 mM EDTA), 0.5% Cadbury's marvel milk powder, 1% SDS, and 6% polyethylene glycol 8,000. The washes were done in I X SSC and 0.1% SDS at 500C. The filters were subjected to autoradiography at -700C for 2-7 d with and without intensifying screens. Losses of fingerprint bands in tumor DNA were ascertained by overexposure of the filters with respect to the other bands.
Statistical methods used included Fisher's exact test (two-tailed) and the Poissonian distribution as appropriate.
Results
In each case the DNA fingerprints detected in DNA from peripheral blood leukocytes and normal gastrointestinal mucosa were indistinguishable. Similarly, no differences were observed between the DNA fingerprints of the normal DNA and the DNA samples extracted from inflammatory lesions in five cases of Crohn's disease. The abnormalities observed in the tumor DNA fingerprints chiefly included novel bands, loss of bands seen in the corresponding normal DNA, and shifts in hybridization intensity between bands in the tumor DNA compared with normal DNA (Table I and Fig. 1 Table II provides a more detailed breakdown of the observed numbers of changes in the tumors compared with the number of expected changes. The number of cases observed with zero, one, or two novel bands or losses did not differ significantly from the numbers expected conforming to a Poissonian distribution. Thus these results are compatible with the hypothesis that each fingerprint band in a tumor has an independent chance of being affected.
Four of the five adenomas showed normal DNA fingerprints. However, one adenoma showed a loss of a band that was present both in the constitutional DNA and the DNA of the colonic carcinoma (case 15). Two patients (Table I, 12 and 37) had two separate colorectal tumors. In case 12 one tumor (12b) showed a normal DNA fingerprint, whereas the other (12a) had a novel band. Case 37 showed losses ofbands with all three probes in one tumor (37a) and with the a-globin 3'HVR only in the other (37b). In two gastric cancers (Table 1,2 and 3) DNA extracted from metastatic tumor in lymph nodes could be studied. In case 2 the primary carcinoma had a normal fingerprint, whereas the metastasis had a novel band. In case 3 the metastasis had novel bands with all three probes, none of which were shared by the primary tumor, which in turn showed a novel band detected by 33.15. markers in a high proportion (66%) of these tumors. The finding that none of our cases showed any differences between the DNA fingerprints of peripheral blood leukocytes and normal replication could result in novel bands or losses of bands (24) . Changes in DNA methylation patterns have been shown to occur in colorectal cancer (25) , which may alter Hinf I cleavage sites. However, abnormal tumor DNA fingerprints were confirmed in both our previous (18) and present reports (data not shown) using restriction enzymes such as Alu I or Hae III, which are not methylation sensitive (26) . For future studies we recommend that Alu I be used as the enzyme of first choice. 
